<DOC>
	<DOC>NCT01175590</DOC>
	<brief_summary>The objective of this study is to evaluate the safety of Besivance (besifloxacin ophthalmic suspension, 0.6%) compared to vehicle.</brief_summary>
	<brief_title>Safety of Besivanceâ„¢ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis, Bacterial</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>7-(3-aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid</mesh_term>
	<criteria>Subjects must have a clinical diagnosis of acute bacterial conjunctivitis and exhibit purulent conjunctival discharge (crusty or sticky eyelids) and redness in at least one eye. Subjects who are willing to discontinue contact lens wear for the duration of the study. Subjects who are able and willing to comply with all treatment and follow up/study procedures. Subjects who have any uncontrolled systemic disease or debilitating disease. Subjects with a known hypersensitivity or contraindications to Besivance, fluoroquinolones, or any of the ingredients in the study drugs. Subjects who are expected to require disallowed concurrent systemic or ocular therapy(either eye)during or prior to study start. (ie, NSAIDs, corticosteroids, mast cell stabilizers, antihistamines, decongestants or antimicrobial therapy) Subjects having ocular surgery (including laser surgery) in either eye within six weeks prior to entry into this study. Subjects with suspected viral or allergic conjunctivitis or any other disease conditions that could interfere with the efficacy and safety evaluations of the study medication. Subjects with suspected iritis. Subjects with a history of recurrent corneal erosion syndrome, either idiopathic or secondary to previous corneal trauma or dry eye syndrome. Subjects with any active ulcerative keratitis, specifically any epithelial loss greater than punctate keratitis. Subjects who are immune compromised.</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>